# Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)

> **NCT03535870** · NA · COMPLETED · sponsor: **West-Ward Pharmaceutical** · enrollment: 1556 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Fluticasone propionate/salmeterol
- **DRUG:** Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03535870
- **Lead sponsor:** West-Ward Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-26
- **Primary completion:** 2019-09-10
- **Final completion:** 2019-09-10
- **Target enrollment:** 1556 (ACTUAL)
- **Last updated:** 2019-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03535870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03535870, "Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03535870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*